Suppression of liver transplant rejection by anti-donor MHC antibodies via depletion of donor immunogenic dendritic cells. (1st December 2020)

• Record Type: Journal Article
• Authors: Ueta, Hisashi; Xu, Xue-Dong; Yu, Bin; Kitazawa, Yusuke; Yu, Enqiao; Hara, Yoshiaki; Morita-Nakagawa, Miwa; Zhou, Shu; Sawanobori, Yasushi; Ueha, Satoshi; Rokutan, Kazuhito; Tanaka, Toshiya; Tokuda, Nobuko; Matsushima, Kouji; Matsuno, Kenjiro
• Is Part Of: International immunology. Volume 33:Number 5(2021)
• Page Start: 261
• Page End: 272
• Publication Date: 2020-12-01
• Subjects: CD8 T cells -- donor-specific transfusion -- leukocyte trafficking -- multicolor immunohistochemistry -- sensitization pathway; Immunology -- Periodicals; 616.079
• DOI: 10.1093/intimm/dxaa076
• Languages: English
• ISSNs: 0953-8178

Abstract

Abstract: Background: We previously found two distinct passenger dendritic cell (DC) subsets in the rat liver that played a central role in the liver transplant rejection. In addition, a tolerance-inducing protocol, donor-specific transfusion (DST), triggered systemic polytopical production of depleting alloantibodies to donor class I MHC (MHCI) antigen (DST-antibodies). Methods: We examined the role of DST-antibodies in the trafficking of graft DC subsets and the alloresponses in a rat model. We also examined an anti-donor class II MHC (MHCII) antibody that recognizes donor DCs more selectively. Results: Preoperative transfer of DST-antibodies or DST pretreatment eliminated all passenger leukocytes, including both DC subsets and depleted the sessile DCs in the graft to ~20% of control. The CD172a + CD11b/c + immunogenic subset was almost abolished. The intrahost direct or semi-direct allorecognition pathway was successfully blocked, leading to a significant suppression of the CD8 + T-cell response in the recipient lymphoid organs and the graft with delayed graft rejection. Anti-donor MHCII antibody had similar effects without temporary graft damage. Although DST pretreatment had a priming effect on the proliferative response of recipient regulatory T cells, DST-primed sera and the anti-donor MHCII antibody did not. Conclusion: DST-antibodies and anti-donor MHCII antibodies could suppress the CD8 + T-cell-mediated liver transplant rejection by depleting donor immunogenic DCs, blocking the direct or semi-direct pathways of allorecognition. Donor MHCII-specific antibodies may be applicable as a selective suppressant of anti-donor immunity for clinical liver transplantation without the cellular damage of donor MHCII – graft cells and recipient cells. Abstract : Antibody-mediated donor-DC depletion prolongs liver-graft survival